Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Therapeutics Report 2016: Pipeline Review of 8 Companies & 11 Drug Profiles - Research and Markets

Research and Markets
Posted on: 19 Oct 16

Research and Markets has announced the addition of the "Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016" report to their offering.

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Our latest report Interleukin 17A - Pipeline Review, H2 2016, outlays comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Interleukin-17A is a protein encoded by the IL17A gene. It acts as a ligand for IL17RA and IL17RC. It is involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 4 and 1 respectively.

Furthermore, this report also reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Interleukin 17A Overview
  3. Therapeutics Development
  4. Pipeline Products for Interleukin 17A - Overview
  5. Pipeline Products for Interleukin 17A - Comparative Analysis
  6. Interleukin 17A - Therapeutics under Development by Companies
  7. Interleukin 17A - Therapeutics under Investigation by Universities/Institutes
  8. Interleukin 17A Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Interleukin 17A - Products under Development by Companies
  13. Interleukin 17A - Products under Investigation by Universities/Institutes
  14. Interleukin 17A - Companies Involved in Therapeutics Development
  15. AbbVie Inc
  • Abeome Corporation
  • Affibody AB
  • Cell Medica Limited
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Orega Biotech SAS

For more information about this report visit http://www.researchandmarkets.com/research/z26mcx/interleukin_17a

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005652/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.